BioAge Labs (BIOA) Stock Price, News & Analysis

Company Overview

BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity. As with other investigational therapies, these programs remain subject to clinical testing and regulatory review.

BioAge was founded in 2015 and is headquartered in Richmond, California. The company was co-founded and is led by Kristen Fortney, who serves as chief executive officer. BioAge Labs became a publicly traded company on the Nasdaq under the ticker symbol BIOA in 2024.

Key Stats

• Today's Range: $5.54 to $5.90
• 50-Day Range: $5.57 to $11.72
• 52-Week Range: $5.04 to $25.95
• Volume: 638,485 shs
• Average Volume: 912,893 shs
• Market Capitalization: $255.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

BioAge Labs Stock Analysis - MarketRank™

BioAge Labs scored higher than 64% of companies evaluated by MarketBeat, and ranked 229th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

BioAge Labs has a consensus price target of $33.00, representing about 492.5% upside from its current price of $5.57.

Amount of Analyst Coverage

BioAge Labs has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAge Labs are expected to grow in the coming year, from ($2.45) to ($2.28) per share.

Price to Book Value per Share Ratio

BioAge Labs has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.65% of the float of BioAge Labs has been sold short.

Short Interest Ratio / Days to Cover

BioAge Labs has a short interest ratio ("days to cover") of 3.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioAge Labs has recently increased by 6.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAge Labs does not currently pay a dividend.

Dividend Growth

BioAge Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.72

News Sentiment

BioAge Labs has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for BioAge Labs this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for BIOA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAge Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.55% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioAge Labs has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BIOA
• Previous Symbol: NYSE:BIOA
• CIK: 1709941
• Web: bioagelabs.com
• Phone: (510) 806-1445
• Fax: N/A
• Employees: 62
• Year Founded: 2015

Price Target and Rating

• Average Price Target for BioAge Labs: $33.00
• High Price Target: $60.00
• Low Price Target: $8.00
• Potential Upside/Downside: +492.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.61 million
• Net Margins: -912.26%
• Pretax Margin: -912.26%
• Return on Equity: -28.99%
• Return on Assets: -27.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.19
• Quick Ratio: 17.19

Sales & Book Value

• Annual Sales: $8.99 million
• Price / Sales: 28.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.59 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 45,900,000
• Free Float: 37,842,000
• Market Cap: $255.66 million
• Optionable: N/A
• Beta: 1.08